Anji Biotech

Our Vision

To become a global leader in the discovery and development of innovative peptide drugs

Focused on original innovative peptide drugs

About Us —
Peptide field
R&D projects
Patents filed

Founded in April 2012, Nanjing Anji Biotech Co., Ltd. is a biotech company focused on the research and development of innovative peptide drugs. It is located in Hongfeng Science & Technology Park of the National Nanjing Economic and Technological Development Zone. The company has been certified as a National High-tech Enterprise for four consecutive terms since 2015.

The company has always been committed to the development of original innovative peptide drugs, creating differentiated products driven by clinical and patient needs. It currently has more than 10 peptide drug pipelines under development, some of which are about to enter Phase II clinical trials, along with over a hundred reserve candidate peptide molecules spanning fields such as rheumatoid arthritis, oncology, pain, fibrosis, AMD and anti-aging. It has filed 210 invention patents in China and abroad, 90 of which have been granted.

High-throughput novel target and micropeptide discovery technology platform

Since peptides opened the modern path of biomedicine, frontier science has been rewriting the code of life. The landmark discovery that non-coding RNA encodes micropeptides has unlocked a treasure trove of novel targets. Seizing the opportunity of the times, Anji Biotech has mastered the core technology for high-throughput discovery of endogenous micropeptides. Rooted in original fundamental theories and translational platforms, the company is exploring the immense value of micropeptides in disease diagnosis and treatment, and pursuing a new generation of innovative drugs.

Technology Platforms —

R&D Pipeline

A multi-tiered product portfolio driven by platform innovation

NameMarket RightsIndicationLeadDrug Candidate
PreclinicalPre-INDINDPhase IPhase IIPhase III
Structure-targeted peptide computer-aided design technology
AJ001GlobalRheumatoid arthritis
AJ002GlobalTumor lymphatic metastasis
AJ003GlobalAnalgesia
AJ004GlobalPulmonary/hepatic fibrosis
AJ007Global (ex-US/CA)wAMD
AJ009Global (ex-US/CA)Tumor PDC
OthersGlobalUndisclosed
Based on high-throughput novel target and micropeptide discovery technology
AJ005Global (ex-US/CA)Tumor or others
AJ012GlobalLipid metabolism
AJ013GlobalEnergy metabolism
AJ014GlobalReproduction

Cooperation Strategy

Nanjing Anji Biotech has been deeply engaged in innovative peptide drug R&D for more than 20 years. Relying on two core platforms — a globally leading high-throughput endogenous micropeptide novel-target discovery technology and China's exclusive fifth-generation structure-targeted peptide intelligent design technology (STP-CADD) — the company focuses on major unmet clinical needs such as oncology, fibrosis, autoimmune diseases, fundus diseases and pain, building an open cooperation system spanning multiple technologies, pipelines and models. Adhering to the philosophy of technological openness, industrial collaboration and shared value creation, Anji Biotech offers diversified cooperation models to domestic and international pharmaceutical companies, research institutions and industrial platforms.

Strategic Cooperation —

Strategic Cooperation

Backed by its two exclusive core technology platforms, the company conducts long-term, in-depth industrial strategic cooperation and joint platform development. With its globally leading endogenous micropeptide discovery technology, it has built a reserve of 25 novel functional micropeptides and a vast pool of first-in-class (FIC) original targets; leveraging China's exclusive STP-CADD intelligent design technology, it can rapidly produce nM-affinity targeting warheads suitable for R&D across all categories of PXC conjugated drugs.

Translational Cooperation

The company has the core capability to continuously generate FIC innovative peptide pipelines, holds a complete portfolio of independent intellectual property, and opens more than ten pipelines under development covering oncology, fibrosis and fundus diseases, jointly advancing clinical and industrial translation to help partners rapidly complete their innovative-drug portfolios.

Joint Development

Addressing the industry pain points of scarce targets and high risk in novel drug R&D, the company opens a full-chain joint development model covering customized targeted-peptide design, PXC conjugated drugs and co-development of endogenous micropeptide therapeutics. Customized R&D services — from molecular design, druggability optimization and efficacy validation to preclinical evaluation — can be tailored to partners' needs.

Other Cooperation

The company engages in various forms of strategic cooperation with research institutions, and domestic and international pharmaceutical and biotech companies, including structure-targeted peptide design and preclinical research and development of drug candidates.

News Center

View More —